The last two decades have seen single-use technologies (SUTs) move from niche innovation to the backbone of modern biopharmaceutical manufacturing. Their ability to enable rapid changeovers between production runs, combined with the elimination of cross-batch contamination, and reduced capital requirements, has transformed how we produce biologics, vaccines, and advanced therapies. Yet, behind these operational gains lies a challenge that is quickly becoming a defining test for our industry: how do we maintain the benefits of single-use while reducing the environmental burden they create?
VectorMine Shutterstock